Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
It has been proposed that hyperlipidemia contributes to the progression of renal diseases, and conversely, that treatment with statins decreases the progressive decline of renal function. Increased glomerular pressure has been found to cause endothelial dysfunction of glomerular capillaries. However, the potential renoprotective effects of statin treatment have not been fully elucidated and so far no study has analyzed the effects of statin treatment on intrarenal hemodynamics. Forty hypercholesterolemic patients were randomly assigned to receive rosuvastatin or placebo in a double-blind crossover study. Renal plasma flow(RPF) and glomerular filtration rate (GFR) were determined by constant input clearance technique with p-aminohippurate (PAH) and inulin. Glomerular hydrostatic pressure (Pglom) and resistances of the afferent(RA) and efferent arterioles (RE) were calculated according to the model originally established by Gomez. RPF and GFR were similar after treatment with rosuvastatin and placebo. Neither Pglom (66.2 +/- 3.9vs. 66.4 +/- 5.1 mm Hg, p=0.861) nor RA (3,200 +/- 1,780 vs.3,188 +/- 1,870 dyn-s-cm-5, p=0.957) or RE (3,620 +/- 1,174vs. 3,490 +/- 1,272 dyn-s-cm-5, p=0.378) were affected by treatment with rosuvastatin, compared with placebo. The beneficial effects on renal function by statin treatment seem not to be mediated by changes in intrarenal hemodynamics in patients with hypercholesterolemia.